Cargando…
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
The understanding of the pathophysiology and the monitoring of metastatic bone disease remains unsatisfactory. We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate. We st...
Autores principales: | Body, J. J., Dumon, J. C., Gineyts, E., Delmas, P. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063380/ https://www.ncbi.nlm.nih.gov/pubmed/9020487 |
Ejemplares similares
-
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells
por: Journe, F, et al.
Publicado: (2004) -
Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy
por: Clements, Miranda E, et al.
Publicado: (2023) -
Inherited multicentric osteolysis: case report of three siblings treated with bisphosphonate
por: Lee, Senq-J, et al.
Publicado: (2010) -
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival
por: Fromigue, O, et al.
Publicado: (2003) -
Inhibitory role of Annexin A1 in pathological bone resorption and therapeutic implications in periprosthetic osteolysis
por: Alhasan, Hend, et al.
Publicado: (2022)